Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by johnny007on Apr 22, 2021 9:16am
139 Views
Post# 33043585

RE:RE:RE:Questions for this Presentation

RE:RE:RE:Questions for this PresentationNo, to pull in material investors he needs to address exactly these questions on financials.

Normally you would file form S-4 in the US, disclosing all of that: Balance sheet, income and cash flow.
This is not a tiny acquisition, but a merger giving roughly 38% to new company
and widening the whole business spectrum.
In the end, the 'new company' will be different.
So this is quite material, see Clarus.

Also, will there be a SH vote at all?
Aren't they required or skipping it,
due to the nature of the 'step-up' consideration?

I keep an eye on this, but as I laid out days ago,
the known information on Health Clinic is not to shiny.

https://stockhouse.com/companies/bullboard?symbol=t.szls&threadid=32971620
https://stockhouse.com/companies/bullboard?symbol=t.szls&threadid=32946564
<< Previous
Bullboard Posts
Next >>